Literature DB >> 12576323

Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.

Veronika Sexl1, Boris Kovacic, Roland Piekorz, Richard Moriggl, Dagmar Stoiber, Angelika Hoffmeyer, Rita Liebminger, Oliver Kudlacek, Eva Weisz, Kristen Rothammer, James N Ihle.   

Abstract

The Janus kinase Jak1 has been implicated in tumor formation by the Abelson oncogene. In this study we show that loss of Jak1 does not affect in vitro transformation by v-abl as defined by the ability to induce cytokine-independent B-cell colony formation or establishment of B-cell lines. However, Jak1-deficient, v-abl-transformed cell lines were more tumorgenic than wild-type cells when transplanted subcutaneously into severe combined immunodeficient (SCID) mice or injected intravenously into nude mice. Jak1 deficiency was associated with a loss in the ability of interferon-gamma (IFN-gamma)to induce growth arrest and/or apoptosis of v-abl-transformed pre-B cells or tumor growth in SCID mice. Moreover, IFN-gamma mRNA could be detected in growing tumors, and tumor cells explanted from SCID mice had lost the ability to respond to IFN-gamma in 9 of 20 cases, whereas the response to interferon-alpha (IFN-alpha) remained intact. Importantly, a similar increase in tumorgenicity was observed when IFN-gamma-deficient cells were injected into SCID mice, identifying the tumor cell itself as the main source of IFN-gamma. These findings demonstrate that Jak1, rather than promoting tumorgenesis as previously proposed, is critical in mediating an intrinsic IFN-gamma-dependent tumor surveillance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576323     DOI: 10.1182/blood-2001-11-0142

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

3.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway.

Authors:  Yutaka Takahashi; Michiko Takahashi; Nick Carpino; Shiann-Tarng Jou; Jyh-Rong Chao; Satoshi Tanaka; Yasufumi Shigeyoshi; Evan Parganas; James N Ihle
Journal:  Mol Endocrinol       Date:  2008-05-01

5.  Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Mari Kasai; Tomoyuki Ichimura; Tamotsu Sudo; Yoh-Ichi Tagawa; Ryuichiro Nishimura; Osamu Ishiko; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Tanri Shiozawa; Ikuo Konishi
Journal:  Sci Rep       Date:  2011-12-05       Impact factor: 4.379

Review 6.  Deregulation of Interferon Signaling in Malignant Cells.

Authors:  Efstratios Katsoulidis; Surinder Kaur; Leonidas C Platanias
Journal:  Pharmaceuticals (Basel)       Date:  2010-02-04

Review 7.  IFN inducibility of major histocompatibility antigens in tumors.

Authors:  Barbara Seliger; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

9.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Authors:  Andrea Hoelbl; Boris Kovacic; Marc A Kerenyi; Olivia Simma; Wolfgang Warsch; Yongzhi Cui; Hartmut Beug; Lothar Hennighausen; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

10.  Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Authors:  Tatsuaki Mizutani; Nina Neugebauer; Eva M Putz; Nadine Moritz; Olivia Simma; Eva Zebedin-Brandl; Dagmar Gotthardt; Wolfgang Warsch; Eva Eckelhart; Hans-Peter Kantner; Ulrich Kalinke; Stefan Lienenklaus; Siegfried Weiss; Birgit Strobl; Mathias Müller; Veronika Sexl; Dagmar Stoiber
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.